Any patient starting either tirzepatide or semaglutide will start at the lowest dose and titrate up, regardless of whether they have previously taken an incretin medication
The long-term maintenance benefit is perhaps the most underappreciated advantage of building fat-adapted metabolism while pharmaceutical appetite suppression is supporting adherence
You are sitting in front of Trava's checkout page with $119.96 a month staring back at you, and the price feels almost too low for a GLP-1 program
Studies have shown that Pip6a-PMO effectively rescues the disease phenotype and improves the survival rate of severe SMA mice, showing strong efficacy in the central nervous system and peripheral tissues
All GLP-1 medications start low and gradually increase every 4 weeks (weekly formulations) or weekly (daily formulations) to minimize gastrointestinal side effects
Single studies aren't enoughI want to see multiple trials, ideally in humans, with consistent results